LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Purge at Orthofix

Purge at Orthofix

September 12, 2023 2 min read Premium comments

Advertisement

Purge at Orthofix
(L to R): Keith Valentine, John Bostjancic, and Patrick Keran
#orthofix#keithvalentineSecondary#seaspine#patrickkeran#johnbostjancic

In a shocking move, Orthofix’s board of directors announced today that they have terminated for cause three of the top executives in the world of spinal implant manufacturing: Keith Valentine, John Bostjancic and Patrick Keran. Valentine was also asked to resign from Orthofix’s board of directors.

Keith Valentine was President and Chief Executive Officer at Orthofix. Over the course of his more than 30 years in the spine industry, Valentine rose from Vice President of Marketing at Medtronic Spine & Biologics to President and Chief Operating Officer at NuVasive, Inc. to President and CEO of SeaSpine. He is one of the most respected and admired executives in the industry.

John Bostjancic has spent more than a quarter century in key executive positions in healthcare starting as Senior Associate at PricewaterhouseCoopers, then Manager of Accounting Standards for Merck, followed a long career at Integra LifeSciences where he started as the Senior Director of Finance and progressed up through the ranks to Senior Vice President, Global Supply Chain. He joined the SeaSpine spin off as its Chief Operating and Financial Officer and then was Chief Financial Officer at Orthofix.

Patrick Keran is a 20-year industry veteran who was Orthofix’s chief legal officer and before that SeaSpine’s Senior Vice President, Corporate Development and General Counsel.

The announcement from Orthofix was released this morning and said, in part:

“Catherine Burzik, Chair of the Orthofix Board of Directors, has been appointed Interim Chief Executive Officer; Geoffrey Gillespie, Orthofix Vice President, Corporate Controller, has been appointed Interim Chief Financial Officer; and Puja Leekha, Orthofix Senior Vice President, Chief Ethics and Compliance Officer, has been appointed Interim Chief Legal Officer. The appointments are effective immediately and follow the unanimous decision by the Board’s independent directors to terminate for cause Keith Valentine, John Bostjancic and Patrick Keran from those respective roles. The Board also requested that Mr. Valentine resign from the Board. The Board will immediately begin a search for permanent successors.”

“The Board’s decision follows an investigation conducted by independent outside legal counsel and directed and overseen by the Company’s independent directors. As a result of the investigation, the Board determined that each of these executives engaged in repeated inappropriate and offensive conduct that violated multiple code of conduct requirements and was inconsistent with the Company’s values and culture. These matters are unrelated to and do not impact the Company’s strategy, results of operations or previously filed financial statements.”

We, like everyone, are shocked and wait for more explanations and information.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy